Phathom Pharmaceuticals, Inc. Average Common Equity

Average Common Equity of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Common Equity growth rates and interactive chart.


Highlights and Quick Summary

  • Average Common Equity for the quarter ending June 29, 2021 was $160 Million (a -14.07% decrease compared to previous quarter)
  • Year-over-year quarterly Average Common Equity increased by 8062.75%
  • Annual Average Common Equity for 2020 was $211 Million (a 86.27% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Common Equity of Phathom Pharmaceuticals, Inc.

Most recent Average Common Equityof PHAT including historical data for past 10 years.

Interactive Chart of Average Common Equity of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Average Common Equity for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $160.28 $186.52
2020 $211.11 $1.96 $93.57 $211.11
2019 $113.33

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.